Overview
With the emergence of antibiotic resistant strains and increase in frequency of enteric fever caused by Salmonella enterica serovar Paratyphi A, there is a critical need for a prophylactic vaccine, as none is currently available. Typhoid fever and paratyphoid fever are clinically indistinguishable, patients having a rash and fever which can lead to severe complications if untreated. Of the two current commercial vaccines for typhoid fever, one may provide moderate cross protection for paratyphoid B and the other lacks cross protection altogether. The Centers for Disease Control estimates 6 million cases of paratyphoid fever occur annually throughout the world, and the highest risk of acquiring a multi-drug resistant infection is in South Asia. In order to develop a vaccine specifically against paratyphoid A fever, researchers at UMB's Center for Vaccine Development have engineered S. Paratyphi A strains with independent attenuating genetic mutations proven to be safe and immunogenic in preclinical tests. One such strain, CVD 1902, is currently being tested in a Phase 1 clinical trial.
Applications
-Oral vaccine against paratyphoid A fever, for use by residents of and travelers to endemic areas. -CVD's attenuated strains also provide safe source of antigenic material and potentially high yield for production of conjugate vaccines.
Advantages
-FIRST AVAILABLE vaccine against enteric fever caused by S. Paratyphi A. -Increasing need for vaccine given emergence of antibiotic resistance to S. Paratyphi. -Vaccine can be delivered orally rather than by injection, so it's likely to be more efficacious for an enteric disease and certainly easier to administer.
Stage of Development
Phase 1 clinical trial in progress.
R&D Required
Completion of clinical development.
Licensing Potential
UMB seeks commercialization partner for advanced clinical development.
Contact Info
Office of Technology Transfer
620 W Lexington St., 4th Floor
Baltimore, MD 21201
Email: [email protected]
Phone: (410) 706-2380